Related Experiment Video
Updated: Apr 5, 2026
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes
Amer M Zeidan1, Franklin Hendrick2, Erika Friedmann3
1Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT 06520, USA.
Aims:
Iron overload adversely affects patients with myelodysplastic syndromes (MDS), but benefits of iron chelation therapy have not been clearly demonstrated. We examined the association between deferasirox (DFX) therapy and mortality in transfusion-receiving Medicare patients.
Patients & Methods:
MDS patients from 2005 to 2008 were identified using ICD-9 codes from 100% Medicare claims. Patients receiving ≥20 blood units were observed until death or end of study. Marginal structural models were used for estimation.
Results:
3926 patients (10.1% used DFX) were observed for a mean of 48.8 weeks. Each incremental week of DFX was associated with a significant reduction in mortality risk (hazard ratio [HR]: 0.989; 95% CI: 0.983-0.996; p = 0.001).
Conclusion:
DFX therapy is associated with a reduced mortality risk among older MDS patients who received a minimum transfusion threshold.
Insights
Deferasirox (DFX) therapy may reduce mortality risk in older patients with myelodysplastic syndromes (MDS) receiving transfusions. This study found a significant association between DFX use and lower mortality rates in this patient group.
Area of Science:
- Hematology
- Clinical Pharmacology
- Geriatric Medicine
Background:
- Iron overload is a significant complication for patients with myelodysplastic syndromes (MDS).
- The benefits of iron chelation therapy in MDS patients remain incompletely defined.
- Understanding the impact of specific therapies on mortality is crucial for this patient population.
Purpose of the Study:
- To investigate the association between deferasirox (DFX) therapy and mortality.
- To evaluate DFX's effect in Medicare patients with MDS who require blood transfusions.
Main Methods:
- Retrospective analysis of 100% Medicare claims data from 2005-2008.
- Identification of MDS patients using ICD-9 codes.
- Application of marginal structural models to assess mortality risk in patients receiving at least 20 blood units.
Main Results:
- The study included 3926 patients, with 10.1% receiving DFX.
- Each additional week of DFX therapy was significantly associated with a reduced mortality risk (HR: 0.989; p = 0.001).
- The mean observation period was 48.8 weeks.
Conclusions:
- Deferasirox (DFX) therapy is linked to decreased mortality risk in older MDS patients.
- This association was observed in patients meeting a minimum blood transfusion threshold.
- DFX may be a beneficial treatment option for managing iron overload and improving survival in this cohort.
More Related Videos
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
06:59Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025